MIDAM-related safety was registered within 45 days after the start of induction. CR was defined as the normalization of blood and bone marrow with ≤5% of blasts, neutrophil count above 1 × 10 9 /L, and platelet count above 100 × 10 9 /L. CRp was defined the same as for CR, but the criteria also included platelet transfusion independence and platelet count remaining below 100 × 10 9 /L. Overall The MIDAM regimen is a valid option for achieving CR in patients with R/R AML. 2 This study aimed to investigate the efficacy and tolerance of this approach in an extended cohort and to analyze the impact of postremission therapy.
We analyzed data from 86 patients with relapsed or refractory AML, which represents the largest series of patients treated with this protocol thus far. The CR rate was 63%, which was in line with the results of a previous phase 2 trial. 2 Disease status before induction of the MIDAM regimen plays an important role in the response to salvage therapy. Indeed, the CR rate was found to be improved in patients with relapsed compared with refractory disease, likely due to the increased incidence of genetic alterations and multidrug resistance phenotype associated with refractory AML. Conversely, no impact of molecular cytogenetic abnormalities was found on response rate, in contrast to results observed in newly diagnosed AML. 4 One major concern is the risk of VOD related to the use of GO, particularly for patients who undergo subsequent allo-HSCT. The use of MIDAM before allo-HSCT is thought to increase this risk. 5 In our cohort, allo-HSCT in patients who achieved CR after the MIDAM regimen was well tolerated and showed an acceptable toxicity profile, and no VOD was found after an extended follow-up.
GO in fractionated doses has been shown to be highly effective in association with chemotherapy and could be an interesting option in our MIDAM regimen because this approach allows the delivery of high cumulative doses without excessive toxicity. 6 In a univariate analysis related to age, this study revealed no significant difference in CR between the different age groups, and the results suggest that the MIDAM regimen could be an acceptable choice as salvage treatment in the elderly. Induction-related death was linked to performance status, with no significant influence of age.
In conclusion, the MIDAM regimen in R/R AML is a viable therapeutic option as salvage chemotherapy and is associated with an acceptable toxicity profile. Allogeneic transplantation is the consolidation of choice and can be performed safely after MIDAM with no increased risk of VOD. To the Editor:
Plasma cell leukemia (PCL) is the most aggressive form of plasma cell dyscrasia. It is characterized by the presence of more than 20% and/or more than 2 × 10 9 /L of circulating plasma cells Primary PCL is one of the most aggressive blood cancers and the therapeutic outcomes of relapsed pPCL patients ineligible for SCT are especially poor. Our patient was not able to undergo SCT because of his cardiac co-morbidities, thus the treatment options remained very limited. Translocation t(11;14) is a routinely investigated cytogenetic abnormality that serves as a useful biomarker predicting sensitivity to venetoclax. This molecular subset is associated with high Bcl-2, and low Bcl-X L and Mcl-1 mRNA expression, resulting in higher sensitivity to Bcl-2 inhibition. In our case we also performed expression profiling of the anti-apoptotic proteins Bcl-1, Bcl-X L , and
Mcl-1 to predict the sensitivity to venetoclax in vitro. 5 We determined Bcl-2/Bcl-X L and Bcl-2/Mcl-1 mRNA ratio using quantitative polymerase chain reaction on FACS sorted PCs. The mRNA ratio of Bcl-2/Bcl-CORRESPONDENCE E35
